Growth until puberty after in utero exposure to coumarins by Rosendaal, F.R.
American Journal of Medical Genetics 95:438-443 (2000)
Growth Until Puberty After In Utero Exposure
to Coumarins
D. Van Driel,1 J. Wesseling,1 F.R. Rosendaal,2 R.J. Odink,1 E. Van der Veer,3* W.J. Gerver,4
L.M. Geven-Boere,5 and P.J.J. Sauer1
1 Department of Pediatrics, Beatrix Children's Hospital, University Hospital Groningen, Groningen, The Netherlands
2Departments of Hematology and Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
3Pathology and Laboratory Medicine, University Hospital Groningen, Groningen, The Netherlands
4Department of Pediatrics, University Hospital Maastricht, Maastricht, The Netherlands
BDutch Föderation of Thrombosis Services, The Hague, The Netherlands
Anticoagulation with coumarins is an effec-
tive therapy during pregnancy. Fetal expo-
sure to coumarin derivatives during the
first trimester, however, is associated with
skeletal anomalies (warfarin or coumarin
embryopathy). Information about long-term
effects of prenatal coumarin exposure on
the skeletal development is not available.
We investigated growth and body propor-
tions at school age of children exposed to
coumarins in utero. A blind population-
based cohort study was conducted on 307
exposed children and 267 non-exposed con-
trols ages 8-15 years. The exposed cohort
was based on a prospective registry of cou-
marin-treated pregnant women. Anthropo-
metric data included height, weight, head
circumference, and measurements to evalu-
ate body proportions. The mean height of
exposed children did not differ from that of
the non-exposed children (mean difference
0.01 SD). In addition, no differences were
found for the proportional measures. As a
group, children exposed in the first trimes-
ter showed no evidence of growth impair-
ment. Two children in this group, however,
were born with signs of coumarin embry-
opathy and one of these displayed a deficit
in height at school age. Long-term growth
was not affected by a high cumulative dos-
age or exposure after the first trimester. We
conclude that, when exposure during the
first trimester is avoided, coumarin therapy
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during pregnancy has no demonstrable risk
for the child's skeletal development. Am. J.
Med. Genet. 95:438-443, 2000.





Anticoagulant therapy during pregnancy is indicated
for the treatment and prophylaxis of thrombo-embolic
disease and prevention of systemic embolism in pa-
tients with valvular heart disease or prosthetic heart
valves [Ginsberg, 1989]. The prescription of anticoagu-
lants during pregnancy must be carefully considered
because of adverse effects in both mother and child.
Heparins have the potential for causing adverse effects
in the mother when . · ' ' Λ
phenprocoumon and . · · · . . · :·
birth defects [Bates and Ginsberg, 1997; Nelson-Piercy,'
1997]. Centers in Europe often use the protocol that
prescribes heparin during the first trimester of gesta-
tion and from the 36th week until birth, whereas cou-
marins are prescribed during the second and third tri-
mester of pregnancy [Lecuru et al., 1996; Harenberg,
1998]. In the United States, heparin is preferred
throughout pregnancy because there is great concern '
about the teratogenic effect of coumarins [Ginsberg
and Barron, 1994; Toglia and Weg, 1996].
Gase reports describe central nervous system
[Kaplan et al., 1982; Lapiedra et al., 1986] and skeletal
abnormalities [Tamburrini et al., 1987; Howe et al.,
1997; Wellesley et al., 1998] after in utero exposure to
coumarins. The bone defects constitute the so-called
'coumarin (or warfarin) embryopathy,' whereas the
term 'coumarin syndrome' refers to the central nervous
system anomalies. Reported skeletal anomalies ob-
served shortly after birth include various degrees of
nasal hypoplasia, rhizomelia, hypoplastic distal pha- *
langes and stippling in epiphyses. There is one report
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of a prenatally exposed child who showed disturbed
growth during childhood resulting in a disproportion-
ally short stature at adult age [Hosenfeld and Wiede-
man, 1989]. In a review of published cases, it was as-
sumed that exposure during the first trimester of
pregnancy, especially from the 6th to the 9th week,
confers the greatest risk for developing the coumarin
embryopathy [Hall et al., 1980].
Animal studies confirm an effect of warfarin expo-
sure on growth. Rats showed a decreased body length
after 12 weeks of postnatal warfarin treatment that
was correlated with calcium bridges in epiphyses
[Howe and Webster, 1992]. Chronic exposure of devel-
oping rats caused growth plate closure resulting in ces-
sation of growth [Price et al., 1982]. It is not clear
whether these findings resemble the skeletal abnor-
malities seen in humans.
So far, growth at school age has not been examined
in children who were prenatally exposed to coumarins.
Knowledge of long-term effects for the child's develop-
ment are essential for a careful consideration of anti-
:oagulant therapy in pregnant women. We performed a
[arge cohort study to assess late effects in children ex-
posed to coumarins in utero. The aim of the present
study is to determine whether prenatal exposure to
:oumarin derivatives causes a (disproportionally) short
stature or other growth impairment at school age.
SUBJECTS AND METHODS
Subjects
Two groups are included in the study: a cohort of
:hildren exposed in utero to coumarin derivatives and
ι cohort of non-exposed controls. The coumarin-
;xposed children were offspring of mothers included
luring pregnancy in a registry by Dutch anticoagula-
ion clinics, charged with monitoring oral anticoagu-
ant therapy in out-patients. Inclusion criteria for the
•xposed study group were: consent for registration,
>rescription of coumarin derivatives during pregnancy
ind childbirth between January Ist, 1982 and Decem-
>er 3Ist, 1990. Eligible registered women were ap-
iroached by the anticoagulation clinics, either directly
•r after consultation with the family's general practi-
ioner. Non-exposed control children were approached
iy regional vaccination centres, keeping records of the
noculation of all children in The Netherlands. Match -
ng was done for age (±1/2 year) and gender to obtain
n equal distribution in both study cohorts, and for
emographic region (postal code) äs a measure of socio-
conomic Status. Exclusion criteria were diseases in-
erfering with growth that are not related to coumarin
xposure, including Down syndrome.
The study protocol was approved by the Medical Eth-
3s Committee of the University Hospital Groningen
nd the parents of all children gave written informed
onsent.
Data Collection
After enrollment in the study, all children received
n appointment for physical examination. Puberty as-
essment included examination of secondary sexual
tiaracteristics according to Tanner [1962]. We consid-
ered breast development Stage 2 in girls and mean
testicular volume of 5 ml in boys äs minimum criteria
for the onset of puberty.
Information about pregnancy, delivery, and the
medical history of the child were obtained by question-
naire. We inquired about parental height and weight
äs references for target height and Body Mass Index of
the child. Maternal education and paternal occupation,
the latter classified according to Sixma and Ultee
[1983], were regarded äs measures of socio-economic
status.
For the exposed cohort, Information about indication,
period, coumarin derivative, and prescribed dosage
during pregnancy was collected from the initial regis-
tration form together with medical records from anti-
coagulation clinics and gynecologists.
Anthropometric Measurements
The anthropometric data were collected by a trained
observer who was not aware of the exposure Status of
the child. Measurements were performed on subjects
wearing light clothing (underwear) and repeated three
times, measuring to the nearest 0.1 cm. Height and
sitting height were measured by two observers; for sit-
ting height the child was placed on a Standard stool
with bis feet on a footrest. Head circumference was
measured with a non-stretchable tape at the most
prominent points of occiput and forehead. Arm span
was measured (with a non-elastic measuring rod) äs
the distance between the tips of the stretched middle
fingers, the child standing with bis arms fully ex-
tended. The different skeletal parts were measured on
the left side of the body using bony prominences äs
anatomical landmarks. Upper arm length was mea-
sured from the lateral border of the acromion to the
head of the radius, lower arm length from the head to
the bottom of the radius, and hand length from the
bottom of the radius to the tip of the longest finger.
Biacromial diameter was measured between the later-
al borders of the acromion processes and bi-iliacal di-
ameter at the widest point of the iliac crests, using the
anterior superior spina iliaca äs a landmark. The dis-
tance from the proximal medial border of the tibia to
the distal border of the medial malleolus was used for
tibia length; the distance between the most posterior
part of the heel and the tip of the longest toe was used
for the foot length. Weight was measured in kilograms,
using a digital scale with an accuracy of 100 g.
Statistical Analysis
To adjust for gender and age, we calculated SD-
scores using Dutch references [Gerver and De Bruin,
1996]. Values were expressed in means ± SD. For the
comparison of weight, Body Mass Index (kg/m2) was
calculated. Statistical differences between exposed and
non-exposed children were assessed by linear regres-
sion analysis, controlling for the confounding variables
gender, age, target height, puberty, and socio-economic
status.
Exposure to coumarins was classified according to
trimester (exposure at least during the first trimester
of pregnancy or exposure only during the second or
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third trimester), derivative (acenocoumarol or phen-
procoumon), and daily dosage. In addition, cumulative
dosage (duration (days) calculated from start and stop
date of therapy multiplied by mean daily dosage) was
used to investigate the combined effect of dosage and
duration of exposure. To disentangle the effect of cou-
niarin exposure from the effect of maternal disease, we
performed a stratified analysis by indication for cou-
marin treatment during pregnancy. The significance
level was set at P < 0.05. Statistical analysis was per-
formed with Statistical Package for the Social Sciences
(SPSS Inc., Chicago, IL).
RESULTS
Study Population
A total of 574 children were enrolled in the study,
307 in the exposed and 267 in the non-exposed cohort,
respectively. For the exposed cohort, 451 pregnancies
registered by Dutch anticoagulation clinics were con-
sidered for inclusion. Fifty-five of these women could
not be traced because of incomplete personal data. Of
14 families, the general practitioner discouraged con-
tact because of death or severe illness of the mother (n
= 6) or because of other familial circumstances (n = 5).
In three cases, the general practitioner did not give an
explication, but the child concerned was healthy. The
remaining 382 registered pregnancies proved eligible
for inclusion; 307 of these children actually partici-
pated in the study (response rate 80%). In 75 cases,
participation was refused because the child was not
willing to cooperate (n = 15), the mother had no con-
tact with the child because of divorce (n = 6), 'taking
part costed too much time' (n = 8), or participation in
the planned investigation period was not possible due
to familial circumstances (n = 4). Forty-three parents
declined participation without explanation.
Characteristics of the exposed and non-exposed co-
hort are presented in Table I. Gestational age was
lower in the exposed study cohort probably related to a
higher percentage of labour induction in this high risk
group (31% vs. 12%, RR = 2.5 CI95 1.7 to 3.5 ). Birth
weight and length, when adjusted for gestational age,
were not significantly different. Age at study was simi-
lar in both groups ranging from 7.6 to 15.3 years. Mean
age at the various stages of puberty, both in boys and in
girls, were not significantly different for the exposed
and non-exposed cohort. For four children (three ex-
posed, one non-exposed) the level of maternal educa-
tion could not be identified.
Exposure
Indications for coumarin derivatives during preg-
nancy were treatment (n = 64) and prophylaxis (n =
207) of thrombo-embolic events, hereditary thrombo-
philia (n = 11), artificial heart valve (n = 10), and a
group of incidental causes like antiphospholipid anti-
body syndrome, trauma, and surgery (n = 9); for six
cases the indication was unknown.
Coumarin derivative and exposure period during
pregnancy could be identified for 281 children (92%).
Most children (n = 240) were exposed during the sec-
ond or third trimester of pregnancy. The first trimester
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*P = 0 01, Mann Whitney U-test
study group was comprised of 41 children, of which20
were exposed during (part of) the teratogenic window
(6th to 9th gestational week). The duration of exposure
ranged from one to 36 weeks (mean: 16 weeks). In most
cases (n = 239) the short-acting coumarin derivative
acenocoumarol was prescribed, whereas 33 mothere
used phenprocoumon. Seven women changed coumarin
derivative during pregnancy and in two cases prepara*
tion could not be retrieved.
The prescribed dosage during pregnancy was avail-
able for 166 subjects (54%) of the exposed cohort. Mea»
daily dosage was 3.3 mg (±1.14) for the group exposed
to acenocoumarol and 3.3 mg (±1.20) for the group ex-
posed to phenprocoumon, respectively. Mean ciunula-
tive dosage including both derivatives was 408.7 i
231.2 mg (ränge: 34.1-1,501.0 mg).
Growth
The mean and Standard deviation of the calculatd
SD-scores of height, sitting height, the proportioi»)
measure sitting height/height and the other growth p*·
rameters of exposed children and non-exposed eontn*
are shown in Table II. Using linear regression analvm
we found no differences for these parameter* betwrt*
both groups. Body Mass Index was not different t*·
tween the exposed and non-exposed cohort (m«w *t!4
ference = -0.01, CI95 -0.42 to 0.41). Children exp^
during the first trimester of pregnancy showrd ffi>«*
ference in height compared with children exP°^f *1
ing the second or third trimester and compa
non-exposed controls (Fig. 1). Two children
during part of the teratogenic window (6th to
tational week) were born with signs of W
bryopathy. One of these children was born ™
manifesting severe growth retardation '
birth length -3.78 and SD-score of birthw«»
both corrected for gestational age). At
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study, this 11-year-old girl displayed a short stature
(SD-score of height-for-age: -1.96, SD-score corrected
for target height: -2.79) with relatively short legs (SD-
score of sitting height/height: 1.43). The other child
was born at 41 weeks with a normal birth length (SD-
score corrected for gestational age: 1.56). At 13 years of
age, he displayed a normal stature (SD-score of height-
for-age: 2.65; SD-score corrected for target height:
1.52), with relatively long legs (SD-score of sitting
height/height: -1.15). Figure 2 shows that there is no
relationship between cumulative dosage of in utero ex-
posure to coumarin derivatives and height at school
age. Using linear regression analysis, we found that
prescribed preparation of coumarin therapy did not
have an influence on long-term height (mean difference
(d) <-0.001 SD for each mg of acenocoumarol and d <
0.001 SD for each mg phenprocoumon). Stratified
analysis showed no differences in height between chil-
dren whose mothers were treated for acute thrombo-
embolism (d = 0.17, Gigs -0.08 to 0.43), prophylaxis of
thromboembolism (d = -0.06, Gigs -0.22 to 0.11), arti-
ficial heart valve (d = 0.45, Gigs -0.15 to 1.04), or
hereditary thrombophilia (d = 0.22, Gigs -0.34 to 0.78)
compared with non-exposed control children.
DISCUSSION
Our study demonstrates that children exposed to
coumarins during pregnancy who are born without
signs of coumarin embryopathy do not differ m growth
with age-matched non-exposed controls. At school age,
we found no differences in various growth parameters
and body proportions between children exposed in
utero to the coumarins acenocoumarol or phenprocou-
mon and non-exposed controls. In addition, time of on-
set of puberty did not differ between the exposed and
non-exposed children. On the other hand, we found two
children who were exposed to coumarins in the first
trimester of pregnancy and were born with manifesta-
tions of coumarin embryopathy. One of these children
was growth retarded at school age.







Fig l Boxplot of the SD score height for age for non-exposed and cou-













Fig 2 Scatterplot of the SD score height for-agevs cumulative dosage
of coumarins dunng piegnancy comparing non-exposed (cumulative dos
age 0 mg) and coumarm-exposed (cumulative dosage 34 1-1,501 0 mg) chil
dren
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marin embryopathy proposes a decreased production of
Vitamin K-dependent mineralization inhibitors in car-
tilage resulting in ectopic calcium deposits in epiphyses
and nasal septum. Experiments in rats showed maxil-
lonasal hypoplasia together with ectopic calcium de-
posits in the septal cartilage of the nasal septum and in
epiphyseal growth plates after warfarin treatment
[Howe and Webster, 1992]. Another theory states that
warfarin inhibits the activity of a novel gene, arylsul-
fatase E, that is assumed to play an important role in
the metabolic pathway of some types of chondrodyspla-
sia punctata [Franco et al., 1995].
Exposure to coumarin derivatives during the first
trimester of gestation, especially from the 6th to the
9th week, carries the greatest risk for inducing skeletal
anomalies. Signs of coumarin embryopathy are de-
scribed in association with exposure to warfarin äs well
äs acenocoumarol and phenprocoumon [Harrod and
Sherrod, 1981; Struwe et al., 1984; De Vries et al.,
1993]; reported prevalence rates vary considerably
from 0-68% [Iturbe-Alessio et al., 1986; Wong et al.,
1993; Sbarouni and Oakley, 1994]. In one case report,
an adult with a disproportionate short stature was de-
scribed after exposure to phenprocoumon during the
first trimester [Hosenfeld and Wiedeman, 1989]. In our
study, 41 children were exposed during the first tri-
mester of gestation; 20 of these were exposed during
(part of) the proposed teratogenic window. Two of the
children who were exposed during the critical period,
were born with signs of coumarin embryopathy. This
suggests a prevalence rate of 10%. Most children (n =
38) were exposed to acenocoumarol, whereas three
were exposed to phenprocoumon. One child exposed in
the critical period was born with signs of classic cou-
marin embryopathy (nasal hypoplasia and stippled
epiphyses) that was diagnosed neonatally. Another
child who was also exposed during the teratogenic win-
dow showed manifestations (nasal hypoplasia with
breathing problems) after birth that retrospectively
suggested an embryopathy. As a group, children ex-
posed in the first trimester showed no evidence of long-
term growth impairment. The child with classic cou-
marin embryopathy, however, showed a short stature
with relatively short legs at the time of study. This
child, born to a mother suffering from systemic lupus
erythematosus, displayed severe growth retardation
(-3.78 SDS) at birth. Although it is difficult to rule out
other influences, the coumarin exposure may have
caused the intrauterine growth retardation, äs well äs
the subsequent growth impairment. The other child
with signs of embryopathy at birth showed a normal
proportional stature at the time of study. The children
in our study who were exposed in the first trimester
and were born without overt manifestations of embry-
opathy had a normal growth at school age.
The vast majority of our study population was ex-
posed during the second and third trimester of preg-
nancy. We found no evidence that a high cumulative
dosage of prenatal exposure to coumarin derivatives
has an effect on growth at school age. The mothers of
these exposed children used either acenocoumarol or
phenprocoumon during pregnancy, with a mean daily
dosage of 3.3 mg. Warfarin-treated postnatal rats
showed a decreased growth that was related to the ex-
posure duration [Price et al., 1982; Howe and Webster,
1992] . In these experiments, the rats were treated with
warfarin in high dosages ranging from 77-100 mg/kg
body weight. Differences in dosage and pharmacokinet-
ics may explain the different outcome of our study com-
pared with those in the rat experiments.
Chong et al. [1984] performed a follow-up study to
assess the growth and development of coumarin-
exposed children compared with non-exposed controls
at 4 years of age. They found no differences in centile
distribution of height between the two study groups.
This study was small (n = 22) and no correction for
target height was made.
The exposed cohort of our study was based upon a
prospective registry of women treated with coumarins
during pregnancy. The response rate of parents and
children that were approached was high (80%). Of the
75 parents who refused to participate in the study, in
32 cases the reason not to participate was not related to
the condition of the child. In 43 cases, parents refused
to cooperate without an explication. Due to privacy rea-
sons, it was not possible to inquire about the reasons to
decline. Taking part in the study was time consuming;
the investigation was carried out during office hours
and lasted for one hour and a half. Because refusal
without explication regarded only 11% of the ap-
proached parents and children (n = 382), the possibil-
ity of selection bias is unlikely.
The present study is the first large cohort study to
date that investigates growth at school age in children
who were prenatally exposed to coumarins. We found
that exposure to the coumarin derivatives acenocouma-
rol and phenprocoumon during the second or third tri-
mester of pregnancy has no effect on growth at school
age. This implies that coumarin therapy during preg-
nancy that adheres to a protocol that avoids treatment
during the first trimester has no demonstrable risk for
the skeletal growth of the exposed child.
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